Mijin Jeon

ORCID: 0000-0003-1400-3029 · 1 paper in corpus
article 2018
·doi:10.1182/blood-2018-99-115931

Abstract Background Improvement of cytopenia is one of the primary treatment purposes for patients with the lower-risk myelodysplastic syndrome (MDS). Androgens have been used for the treatment of aplastic anemia, immune thrombocytopenia, a…